S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.50 (+0.69%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.75 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.40 (+19.40%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.50 (+0.69%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.75 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.40 (+19.40%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.50 (+0.69%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.75 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.40 (+19.40%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
S&P 500   3,638.35 (+0.24%)
DOW   29,910.37 (+0.13%)
QQQ   298.90 (+0.88%)
AAPL   116.45 (+0.36%)
MSFT   215.19 (+0.62%)
FB   277.50 (+0.69%)
GOOGL   1,785.94 (+1.24%)
AMZN   3,197.04 (+0.38%)
TSLA   585.85 (+2.06%)
NVDA   530.10 (+0.13%)
BABA   276.75 (-0.35%)
CGC   29.00 (+7.93%)
GE   10.40 (-0.95%)
MU   64.23 (+1.26%)
AMD   87.18 (+0.54%)
T   29.03 (+0.14%)
NIO   54.16 (+0.88%)
F   9.10 (+0.22%)
ACB   10.40 (+19.40%)
NFLX   491.36 (+1.31%)
BA   216.66 (-0.44%)
GILD   59.99 (+0.82%)
DIS   147.01 (-1.40%)
Log in
NYSE:MNK

Mallinckrodt Competitors

$0.29
+0.02 (+7.41 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.27
Now: $0.29
$0.40
50-Day Range
$0.09
MA: $0.30
$1.09
52-Week Range
$0.75
Now: $0.29
$6.42
Volume1.84 million shs
Average Volume6.49 million shs
Market Capitalization$24.53 million
P/E RatioN/A
Dividend YieldN/A
Beta3.06

Competitors

Mallinckrodt (NYSE:MNK) Vs. SBPH, VRNA, OBSV, KZIA, ARAV, and RMTI

Should you be buying MNK stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Mallinckrodt, including Spring Bank Pharmaceuticals (SBPH), Verona Pharma (VRNA), ObsEva (OBSV), Kazia Therapeutics (KZIA), Aravive (ARAV), and Rockwell Medical (RMTI).

Spring Bank Pharmaceuticals (NASDAQ:SBPH) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, dividends, risk, earnings, profitability and valuation.

Earnings & Valuation

This table compares Spring Bank Pharmaceuticals and Mallinckrodt's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Spring Bank PharmaceuticalsN/AN/A$-24,100,000.00($1.47)-3.80
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03

Spring Bank Pharmaceuticals has higher earnings, but lower revenue than Mallinckrodt. Spring Bank Pharmaceuticals is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Spring Bank Pharmaceuticals and Mallinckrodt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Spring Bank PharmaceuticalsN/A-89.89%-52.89%
Mallinckrodt-89.94%34.26%6.66%

Risk and Volatility

Spring Bank Pharmaceuticals has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Spring Bank Pharmaceuticals and Mallinckrodt, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Spring Bank Pharmaceuticals03102.25
Mallinckrodt46001.60

Spring Bank Pharmaceuticals currently has a consensus target price of $1.7333, suggesting a potential downside of 68.94%. Mallinckrodt has a consensus target price of $2.70, suggesting a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts clearly believe Mallinckrodt is more favorable than Spring Bank Pharmaceuticals.

Institutional and Insider Ownership

17.2% of Spring Bank Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are owned by institutional investors. 12.7% of Spring Bank Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Mallinckrodt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Mallinckrodt beats Spring Bank Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

Verona Pharma (NASDAQ:VRNA) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Risk & Volatility

Verona Pharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500.

Earnings and Valuation

This table compares Verona Pharma and Mallinckrodt's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verona PharmaN/AN/A$-40,780,000.00($3.10)-2.34
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03

Verona Pharma has higher earnings, but lower revenue than Mallinckrodt. Verona Pharma is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Verona Pharma and Mallinckrodt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verona PharmaN/A-115.93%-73.68%
Mallinckrodt-89.94%34.26%6.66%

Analyst Recommendations

This is a summary of current ratings and price targets for Verona Pharma and Mallinckrodt, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verona Pharma00403.00
Mallinckrodt46001.60

Verona Pharma currently has a consensus price target of $22.75, indicating a potential upside of 213.36%. Mallinckrodt has a consensus price target of $2.70, indicating a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts clearly believe Mallinckrodt is more favorable than Verona Pharma.

Institutional & Insider Ownership

54.5% of Verona Pharma shares are held by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are held by institutional investors. 3.1% of Mallinckrodt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Mallinckrodt beats Verona Pharma on 9 of the 13 factors compared between the two stocks.

Mallinckrodt (NYSE:MNK) and ObsEva (NASDAQ:OBSV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Mallinckrodt and ObsEva, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mallinckrodt46001.60
ObsEva11402.50

Mallinckrodt presently has a consensus price target of $2.70, indicating a potential upside of 831.03%. ObsEva has a consensus price target of $14.3333, indicating a potential upside of 589.10%. Given Mallinckrodt's higher possible upside, analysts plainly believe Mallinckrodt is more favorable than ObsEva.

Risk and Volatility

Mallinckrodt has a beta of 3.06, meaning that its stock price is 206% more volatile than the S&P 500. Comparatively, ObsEva has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.

Earnings & Valuation

This table compares Mallinckrodt and ObsEva's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03
ObsEvaN/AN/A$-108,790,000.00($2.49)-0.84

ObsEva has lower revenue, but higher earnings than Mallinckrodt. ObsEva is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mallinckrodt and ObsEva's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mallinckrodt-89.94%34.26%6.66%
ObsEvaN/A-195.77%-86.73%

Institutional & Insider Ownership

61.7% of Mallinckrodt shares are owned by institutional investors. Comparatively, 48.5% of ObsEva shares are owned by institutional investors. 3.1% of Mallinckrodt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Mallinckrodt beats ObsEva on 9 of the 13 factors compared between the two stocks.

Kazia Therapeutics (NASDAQ:KZIA) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Valuation & Earnings

This table compares Kazia Therapeutics and Mallinckrodt's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kazia Therapeutics$710,000.00136.57$-8,370,000.00($1.30)-7.88
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03

Kazia Therapeutics has higher earnings, but lower revenue than Mallinckrodt. Kazia Therapeutics is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Kazia Therapeutics has a beta of 2.45, suggesting that its stock price is 145% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, suggesting that its stock price is 206% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Kazia Therapeutics and Mallinckrodt, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kazia Therapeutics0000N/A
Mallinckrodt46001.60

Mallinckrodt has a consensus price target of $2.70, indicating a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts plainly believe Mallinckrodt is more favorable than Kazia Therapeutics.

Profitability

This table compares Kazia Therapeutics and Mallinckrodt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kazia TherapeuticsN/AN/AN/A
Mallinckrodt-89.94%34.26%6.66%

Insider and Institutional Ownership

11.9% of Kazia Therapeutics shares are held by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are held by institutional investors. 1.0% of Kazia Therapeutics shares are held by insiders. Comparatively, 3.1% of Mallinckrodt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Mallinckrodt beats Kazia Therapeutics on 9 of the 12 factors compared between the two stocks.

Aravive (NASDAQ:ARAV) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, risk, analyst recommendations, valuation and institutional ownership.

Insider & Institutional Ownership

51.2% of Aravive shares are owned by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are owned by institutional investors. 30.5% of Aravive shares are owned by insiders. Comparatively, 3.1% of Mallinckrodt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Aravive and Mallinckrodt's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$4.75 million19.07$-18,220,000.00($1.57)-3.59
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03

Aravive has higher earnings, but lower revenue than Mallinckrodt. Aravive is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aravive and Mallinckrodt, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aravive01602.86
Mallinckrodt46001.60

Aravive currently has a consensus price target of $26.20, suggesting a potential upside of 365.36%. Mallinckrodt has a consensus price target of $2.70, suggesting a potential upside of 831.03%. Given Mallinckrodt's higher probable upside, analysts plainly believe Mallinckrodt is more favorable than Aravive.

Risk and Volatility

Aravive has a beta of 3.26, indicating that its stock price is 226% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, indicating that its stock price is 206% more volatile than the S&P 500.

Profitability

This table compares Aravive and Mallinckrodt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AraviveN/A-47.21%-39.11%
Mallinckrodt-89.94%34.26%6.66%

Rockwell Medical (NASDAQ:RMTI) and Mallinckrodt (NYSE:MNK) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Profitability

This table compares Rockwell Medical and Mallinckrodt's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Rockwell Medical-47.94%-146.49%-55.15%
Mallinckrodt-89.94%34.26%6.66%

Insider & Institutional Ownership

21.1% of Rockwell Medical shares are owned by institutional investors. Comparatively, 61.7% of Mallinckrodt shares are owned by institutional investors. 4.7% of Rockwell Medical shares are owned by insiders. Comparatively, 3.1% of Mallinckrodt shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Rockwell Medical and Mallinckrodt's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rockwell Medical$61.30 million1.62$-34,130,000.00($0.56)-1.89
Mallinckrodt$3.16 billion0.01$-996,500,000.00$8.880.03

Rockwell Medical has higher earnings, but lower revenue than Mallinckrodt. Rockwell Medical is trading at a lower price-to-earnings ratio than Mallinckrodt, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for Rockwell Medical and Mallinckrodt, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Rockwell Medical00103.00
Mallinckrodt46001.60

Rockwell Medical presently has a consensus price target of $9.00, indicating a potential upside of 749.06%. Mallinckrodt has a consensus price target of $2.70, indicating a potential upside of 831.03%. Given Mallinckrodt's higher possible upside, analysts clearly believe Mallinckrodt is more favorable than Rockwell Medical.

Risk & Volatility

Rockwell Medical has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500. Comparatively, Mallinckrodt has a beta of 3.06, indicating that its share price is 206% more volatile than the S&P 500.

Summary

Mallinckrodt beats Rockwell Medical on 8 of the 14 factors compared between the two stocks.


Mallinckrodt Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Spring Bank Pharmaceuticals logo
SBPH
Spring Bank Pharmaceuticals
0.8$5.58+3.0%$96.35 millionN/A-3.21
Verona Pharma logo
VRNA
Verona Pharma
1.7$7.26+0.3%$95.59 millionN/A-2.21
ObsEva logo
OBSV
ObsEva
1.4$2.08+6.3%$93.60 millionN/A-0.84
KZIA
Kazia Therapeutics
0.4$10.25+3.9%$93.18 million$710,000.00-7.88
ARAV
Aravive
1.5$5.63+2.8%$93.16 million$4.75 million-2.75Analyst Downgrade
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$1.06+6.1%$93.11 million$61.30 million-2.36
Leap Therapeutics logo
LPTX
Leap Therapeutics
1.5$1.61+6.8%$89.49 millionN/A-1.21
NRBO
NeuroBo Pharmaceuticals
1.6$5.36+0.7%$88.71 millionN/A-1.31
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.5$0.57+3.3%$86.44 millionN/A-0.06
Eyenovia logo
EYEN
Eyenovia
1.5$3.65+5.5%$85.85 millionN/A-3.15
Synlogic logo
SYBX
Synlogic
1.6$2.45+0.0%$85.34 million$2.22 million-1.48Analyst Downgrade
Unusual Options Activity
Capricor Therapeutics logo
CAPR
Capricor Therapeutics
1.2$4.26+5.4%$82.40 million$1 million-3.98
APM
Aptorum Group
0.5$2.46+5.3%$81.63 million$540,000.000.00Heavy News Reporting
Gemphire Therapeutics logo
GEMP
Gemphire Therapeutics
0.5$5.40+0.7%$80.31 millionN/A0.00
Clearside Biomedical logo
CLSD
Clearside Biomedical
1.5$1.95+0.5%$80.27 million$2.17 million-6.09Insider Buying
Evoke Pharma logo
EVOK
Evoke Pharma
1.4$3.01+0.3%$79.70 millionN/A-6.27
Galmed Pharmaceuticals logo
GLMD
Galmed Pharmaceuticals
1.5$4.15+9.2%$79.60 million$2.04 million-3.61Analyst Report
KemPharm logo
KMPH
KemPharm
1.4$1.10+1.8%$79.58 million$12.84 million-1.92
MRKR
Marker Therapeutics
1.1$1.69+2.4%$79.24 million$210,000.00-3.31
Satsuma Pharmaceuticals logo
STSA
Satsuma Pharmaceuticals
1.4$4.68+3.0%$79.10 millionN/A-1.11
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$4.41+26.8%$75.99 million$2.70 million-13.36Earnings Announcement
Unusual Options Activity
SCYNEXIS logo
SCYX
SCYNEXIS
1.4$6.75+0.9%$74.50 million$120,000.00-1.37
Immutep logo
IMMP
Immutep
1.3$1.90+1.6%$72.93 million$4.92 million0.00
ZOM
Zomedica
1.3$0.13+6.1%$70.73 millionN/A-1.34
Aridis Pharmaceuticals logo
ARDS
Aridis Pharmaceuticals
1.2$7.01+2.4%$70.59 million$1.02 million-2.83Analyst Revision
Savara logo
SVRA
Savara
1.6$1.33+3.0%$69.84 millionN/A-0.92
MITO
Stealth BioTherapeutics
1.3$1.31+0.8%$68.80 million$21.09 million32.76
Bellerophon Therapeutics logo
BLPH
Bellerophon Therapeutics
1.9$6.80+4.4%$67.72 millionN/A-2.05
Novan logo
NOVN
Novan
1.2$0.50+5.0%$67.22 million$4.90 million-2.27
AGE
AgeX Therapeutics
0.5$1.74+4.6%$66.33 million$1.73 million-5.80
Kitov Pharma logo
KTOV
Kitov Pharma
1.4$4.22+3.3%$64.16 million$1 million-1.41
ETTX
Entasis Therapeutics
1.8$1.76+0.9%$62.79 million$7 million-0.52
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.2$0.77+3.8%$62.16 millionN/A-1.60
Soligenix logo
SNGX
Soligenix
1.4$2.21+6.8%$61.49 million$4.60 million-3.16
ASLAN Pharmaceuticals logo
ASLN
ASLAN Pharmaceuticals
1.2$1.87+2.7%$59.93 million$3 million-1.73
MREO
Mereo BioPharma Group
0.6$2.45+3.3%$59.01 millionN/A-0.98
TRVI
Trevi Therapeutics
1.7$3.05+1.3%$56.80 millionN/A-2.05
Recro Pharma logo
REPH
Recro Pharma
1.8$2.49+4.4%$56.28 million$99.22 million12.45
MNPR
Monopar Therapeutics
1.5$4.90+0.6%$56.12 millionN/A-10.89
Avenue Therapeutics logo
ATXI
Avenue Therapeutics
1.2$3.44+3.2%$55.10 millionN/A-5.29Upcoming Earnings
Proteostasis Therapeutics logo
PTI
Proteostasis Therapeutics
1.4$1.08+2.8%$54.79 million$5 million-1.29
Vascular Biogenics logo
VBLT
Vascular Biogenics
1.3$1.26+2.0%$51.78 million$560,000.00-2.14
PLx Pharma logo
PLXP
PLx Pharma
0.9$5.60+0.9%$51.27 million$570,000.00-7.57Analyst Downgrade
Conatus Pharmaceuticals logo
CNAT
Conatus Pharmaceuticals
0.7$1.54+0.6%$51.08 million$21.72 million-5.13
Merrimack Pharmaceuticals logo
MACK
Merrimack Pharmaceuticals
0.7$3.83+1.3%$50.58 millionN/A0.00
Daré Bioscience logo
DARE
Daré Bioscience
1.4$1.35+1.5%$50.53 millionN/A-1.50
Citius Pharmaceuticals logo
CTXR
Citius Pharmaceuticals
1.5$0.98+3.7%$49.93 millionN/A0.00
EDSA
Edesa Biotech
0.7$5.24+1.1%$49.89 million$210,000.00-8.88
Diffusion Pharmaceuticals logo
DFFN
Diffusion Pharmaceuticals
1.4$0.77+0.7%$49.65 millionN/A-0.44
Onconova Therapeutics logo
ONTX
Onconova Therapeutics
1.3$0.27+0.2%$49.20 million$2.18 million-0.18
This page was last updated on 11/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.